Condensed Consolidated Balance Sheets (Unaudited) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2012	Dec. 31, 2011
Current assets:
Cash and cash equivalents	$ 148,485	$ 15,312
Short-term investments	233,624	225,856
Accounts receivable	10,803	4,938
Inventory	14,108	12,656
Other current assets	13,634	17,944
Total current assets	420,654	276,706
Long-term investments	116,732	173,768
Property and equipment, net	75,557	78,576
Goodwill	76,501	76,501
Other assets	5,345	999
Total assets	694,789	606,550
Current liabilities:
Accounts payable	1,761	3,019
Accrued compensation	8,187	12,807
Accrued expenses	7,759	6,669
Accrued clinical trial expenses	12,726	11,953
Deferred revenue, current portion	20,007	19,643
Convertible subordinated notes	214,955	214,955
Other current liabilities	5,358	6,486
Total current liabilities	270,753	275,532
Capital lease obligations, less current portion	13,890	14,582
Liability related to sale of future royalties	125,785
Deferred revenue, less current portion	111,050	108,188
Other long-term liabilities	10,824	10,437
Total liabilities	532,302	408,739
Commitments and contingencies
Stockholders' equity:
Preferred stock, 10,000 shares authorized, $0.0001 par value; 3,100 shares designated Series A and no shares issued or outstanding at December 31, 2011; no shares authorized, issued or outstanding at March 31, 2012
Common stock, $0.0001 par value; 300,000 authorized; 114,591 shares and 114,485 shares issued and outstanding at March 31, 2012 and December 31, 2011, respectively	11	11
Capital in excess of par value	1,602,141	1,597,428
Accumulated other comprehensive loss	(43)	(1,103)
Accumulated deficit	(1,439,622)	(1,398,525)
Total stockholders' equity	162,487	197,811
Total liabilities and stockholders' equity	$ 694,789	$ 606,550